Adenosine A2A receptor antagonist
Adenosine A2A Receptor Antagonist[edit]
An adenosine A2A receptor antagonist is a type of pharmacological agent that inhibits the action of the adenosine A2A receptor. These receptors are a class of G protein-coupled receptors that are activated by the endogenous nucleoside adenosine. Antagonists of the adenosine A2A receptor have been studied for their potential therapeutic effects in various neurological disorders, including Parkinson's disease and Huntington's disease.
Mechanism of Action[edit]
Adenosine A2A receptor antagonists work by blocking the action of adenosine at the A2A receptor sites. Adenosine is a neuromodulator with inhibitory effects in the central nervous system (CNS). By inhibiting these receptors, A2A antagonists can enhance dopaminergic neurotransmission, which is beneficial in conditions like Parkinson's disease where dopaminergic activity is compromised.
Therapeutic Applications[edit]
Adenosine A2A receptor antagonists have been explored for their use in treating neurodegenerative diseases. In Parkinson's disease, these antagonists can help alleviate motor symptoms by modulating the dopamine pathways. They are also being investigated for their potential in treating depression, anxiety, and cognitive disorders.
Examples of Adenosine A2A Receptor Antagonists[edit]
Caffeine[edit]
Caffeine is a well-known adenosine A2A receptor antagonist. It is a methylxanthine that is widely consumed in beverages such as coffee and tea. Caffeine's antagonistic action on adenosine receptors contributes to its stimulating effects.
Istradefylline[edit]
Istradefylline is a selective adenosine A2A receptor antagonist that has been approved for use in Japan and the United States as an adjunctive treatment for Parkinson's disease.
Xanthines[edit]
Xanthines, including caffeine, are a class of compounds that act as adenosine receptor antagonists. They are characterized by their xanthine core structure.
Non-Xanthine Based Antagonists[edit]
Monocyclic[edit]
Monocyclic non-xanthine based antagonists are a diverse group of compounds that have been developed to target the adenosine A2A receptor.
Bicyclic[edit]
Bicyclic non-xanthine based antagonists are another class of compounds with potential therapeutic applications in modulating adenosine receptor activity.
Tricyclic[edit]
Tricyclic non-xanthine based antagonists represent a further evolution in the design of adenosine A2A receptor antagonists, offering unique structural properties.
Related Pages[edit]
Gallery[edit]
-
Structure of Caffeine
-
Structure of Istradefylline
-
Structure of Xanthines
-
Core structures of monocyclic non-xanthine based antagonists
-
Core structures of bicyclic non-xanthine based antagonists
-
Core structures of tricyclic non-xanthine based antagonists
Adenosine A2A receptor antagonist[edit]
-
Caffeine structure
-
Istradefylline structure
-
Xanthines structure
-
Examples of core structures of monocyclic non-Xanthine based adenosine A2A antagonists
-
Examples of core structures of bicyclic non-Xanthine based adenosine A2A antagonists
-
Examples of core structures of tricyclic non-Xanthine based adenosine A2A antagonists
